Vadadustat, sold under the brand name Vafseo, is a medication used for the treatment of symptomatic anemia associated with chronic kidney disease.[2][3] Vadadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor.[2]
Clinical data | |
---|---|
Trade names | Vafseo |
Other names | AKB-6548, PG-1016548 |
License data |
|
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
PDB ligand |
|
ECHA InfoCard | 100.248.991 |
Chemical and physical data | |
Formula | C14H11ClN2O4 |
Molar mass | 306.70 g·mol−1 |
3D model (JSmol) |
|
| |
|
The most common side effects include thromboembolic events (problems due to the formation of blood clots in the blood vessels), diarrhea, and hypertension (high blood pressure).[3]
Vadadustat was approved for medical use in the European Union in April 2023,[3] and in the United States in March 2024.[2]
In the EU, vadadustat is indicated for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.[3]
In the US, vadadustat is indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.[2]
In February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vafseo, intended for the treatment of symptomatic anemia in adults with chronic kidney disease who are on chronic dialysis.[4] The applicant for this medicinal product is Akebia Europe Limited.[4] Vadadustat was approved for medical use in the European Union in April 2023.[3]
Vadadustat is in phase III clinical trials for the treatment of anemia caused by chronic kidney disease.[5][6][7][8][9]
{{cite journal}}
: CS1 maint: overridden setting (link)
{{cite journal}}
: CS1 maint: overridden setting (link)